Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Ovarian carcinoma Age: Adult Condition: Primary treatment (in combination with cisplatin or carboplatin) |
Dose: Intravenous – 135 mg/m2 Frequency: repeated at 3 week intervals Duration: infused over 24 hours Note: followed by cisplatin |
|
Indication: Ovarian carcinoma Age: Adult Condition: Secondary treatment (as single agent) |
Dose: Intravenous – 135 or 175 mg/m2 Frequency: once every 3 weeks Duration: infused over 3 hours |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Child |
Dose: Safety and efficacy not established Note: Not recommended |
Administration
- For IV use only
- Must be diluted before use
Side Effect
- Neutropenia (78-100%)
- Alopecia (55-96%)
- Anemia (47-96%)
- Arthralgia/myalgia (93%)
- Diarrhea (90%)
- Leukopenia (90%)
- Nausea/vomiting (9-88%)
- Opportunistic infections (76%)
- Peripheral neuropathy (42-79%)
- Thrombocytopenia (4-68%)
- Mucositis (5-45%)
- Hypersensitivity (2-45%)
- Renal impairment (34%)
- Hypotension (17%)
- Bradycardia (3%)
- Grand mal seizures
- Cardiac conduction abnormalities
- Pyrexia
- Dehydration
- Pancytopenia
- Congestive heart failure
- Left ventricular dysfunction
- Stevens-Johnson syndrome
- toxic epidermal necrolysis
- extravasation
- Infections and infestations leading to death eg pneumonia and peritonitis
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Cisplatin
|
Myelosuppression was more profound when given after cisplatin
|
|
Carbamazepine, Phenobarbital, Phenytoin, Rifampicin, Rifapentine, Secobarbital
|
May reduce levels or effects
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
History of Hypersensitivity
|
Severe allergic reactions possible
|
|
Baseline Neutropenia (<1500 cells/mm3)
|
Increased infection risk
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Details coming soon
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.